Apr 22 |
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
|
Apr 8 |
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
|
Mar 21 |
Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?
|
Mar 19 |
Adicet Bio: Q4 Earnings Insights
|
Mar 19 |
Adicet Bio GAAP EPS of -$0.69 beats by $0.01
|
Mar 19 |
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
|
Mar 11 |
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
|
Feb 13 |
Jones upgrades Adicet to buy, cites upcoming catalysts
|
Feb 5 |
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
|
Jan 25 |
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
|